Yahoo Finance 1 Reason Dynavax Technologies Corporation Stock Soared in 2017
What happened
Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) had a banner year in 2017. Impressively, the biotech's shares rose by a jaw-dropping 373% last year, according to data from S&P Global Market Intelligence.
The impetus behind Dyanvax's quantum leap higher was the FDA approval of its two-dose hepatitis B vaccine, Heplisav-B, in November. Heplisav-B is the first FDA-approved hepatitis B vaccine in 25 years.
Image source: Getty Images.
So what
As a more convenient and effective option compared with the currently approved hepatitis B vaccines on the market from GlaxoSmithKline and Merck, Heplisav-B is forecast to eventually become the market share leader. As such, it has the potential to generate between $500 million and $600 million in sales.
Now what
Heplisav-B may not get off to a particularly roaring start, however. The company, after all, lacks the experience and financial resources necessary to compete on even-footing against either Glaxo or Merck. In fact, Wall Street's consensus estimate has Heplisav-B generating a rather meager $53 million in sales this year.
Investors were thus hoping to get word of a lucrative licensing deal -- or perhaps an outright acquisition -- before the vaccine's scheduled launch in the first-quarter of 2018. So far, though, there doesn't seem to be that much interest in Dynavax or its newly approved hepatitis B vaccine from Big Pharma.
A potential deal, therefore, seems to hinge on how well Dynavax handles the vaccine's initial launch. But the odd twist is that if Heplisav-B exceeds expectations, Dynavax may no longer be willing to entertain a licensing deal.
As there's no way to tell how this pivotal commercial launch will unfold, however, risk-adverse investors may want to take a wait-and-see approach with this early commercial-stage biotech. A slow start, after all, could result in an emotionally charged sell-off that largely ignores Heplisav-B's long-term commercial prospects.
More From The Motley Fool
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends GlaxoSmithKline. The Motley Fool has a disclosure policy.
